查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2017508

嗜伊紅性食道炎（EoE）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

Eosinophilic Esophagitis (EoE) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 156 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 美國末期（EoE）治療市場預計將從 2025 年的 2.71 億美元成長到 2035 年的 3.7 億美元，預測期內複合年成長率為 3.2% 至 3.5%。
  • 短期成長（2025-2030 年）相對強勁，這主要得益於生物製藥的普及和診斷率的提高。
  • PPI 佔據市場主導地位（佔 36-40% 的佔有率），並且由於其成本效益和可及性，仍然是首選治療方法。
  • 局部皮質類固醇（Fluticasone、Budesonide）合計佔市場佔有率的 25-30%。
  • 生物製藥（Dupixent/Dupilumab）是一個高成長領域，預計市場佔有率將從 2025 年的 4% 穩步成長到 2035 年的 4.6% 以上。
  • AK002（relenterimab）、tezeperumab 和 APT-1011 等新興治療方法預計將促進收入成長，到 2035 年總合將超過 7,000 萬美元。
  • 雖然藥物治療是主要方法，但飲食療法和支持性護理雖然不太普遍，但在臨床上仍佔有重要地位。

嗜伊紅性食道炎（EoE）概述

嗜伊紅性食道炎（EoE），常被稱為“食道氣喘”，是一種慢性免疫介導的2型發炎性疾病，其特徵是食道黏膜中大量嗜酸性粒細胞浸潤，導致進行性結構重塑和功能障礙。此病由Th2介導的免疫通路觸發，並與氣喘、過敏性鼻炎、濕疹和食物過敏等特異性疾病密切相關。內視鏡切片檢查可確診，病灶侷限於食道，且高倍視野下嗜酸性粒細胞數（eos/hpf）超過15個。

嗜酸性粒細胞性食道炎的臨床症狀隨年齡而異。在兒童患者中，嘔吐、腹痛、逆流和進食困難較為常見；而在青少年和成人患者中，吞嚥困難、食物滯留和胸部不適（通常與纖維性狹窄的改變有關）是典型症狀。

這種疾病呈進行性發展，如果不加以適當治療，可能會從發炎性狹窄轉變為纖維性狹窄。

目前的治療策略包括質子幫浦阻斷劑（PPI）、局部皮質類固醇（如Budesonide和Fluticasone）、飲食療法，以及用於中度至重度病例的生物製藥（如度普利尤單抗）。對於難治性或重症患者，生物製藥如度普利尤單抗（一種IL-4/IL-13抑制劑）透過靶向潛在的免疫通路，顯著改善了治療效果。

儘管治療方法取得了進展，但嗜酸性粒細胞性食道炎仍然是一種慢性複發性疾病，需要長期管理，目前還沒有根治性或緩解疾病的治療方法。

主要亮點

  • 據估計，2025年美國新患者數為27,008例，預計到2035年將增加至28,897例。這一穩步成長反映了診斷技術的進步和人們對該疾病認知的提高。
  • 受影響的人數明顯更多，預計將從 2025 年的 53,671 人增加到 2035 年的 57,423 人，這凸顯了該疾病的慢性性質以及患者患病的長期過程。
  • 預計到 2025 年確診患者人數為 46,693 人，到 2035 年將增至 49,958 人。這表明診斷率正在逐步提高，但仍表明患病率和診斷率之間存在差距。
  • 這種疾病在男性中更為常見，預計到 2035 年，男性患者人數將超過女性患者人數（比例為 2.2 比 1）。
  • EoE 影響範圍很廣，年齡範圍很廣，在青年和中年人（21-40 歲）中的發病率最高，但兒童病例也佔據著重要的臨床地位。
  • 大多數病例為中度，其次是重度病例和輕度病例。
  • 吞嚥困難是最常見的症狀，2025 年有 29,948 名患者受其影響，預計到 2035 年將增加到 32,042 名患者。其次是腹痛/消化不良和食道結構併發症。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物核准和順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Sanofi
  • AstraZeneca
  • NexEos Diagnostics, Inc.
  • Celldex Therapeutics
  • Eupraxia Pharmaceuticals Inc.
  • Revolo Biotherapeutics
  • Celgene
  • Ellodi Pharmaceuticals, LP
  • Phathom Pharmaceuticals, Inc.
  • AQILION AB
  • Uniquity One（UNI）
  • Regeneron Pharmaceuticals

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
    • 重點
    • 診斷和治療過程/演算法
    • 主要治療方法概述及KOL洞察
  • 新興治療方法
    • 重點
    • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
    • 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

  • 主要未滿足的需求以及透過新興治療方法實現的未來可能性
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Eosinophilic Esophagitis (EoE) Market Outlook

Thelansis's "Eosinophilic Esophagitis (EoE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Eosinophilic Esophagitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Eosinophilic Esophagitis (EoE) Overview

Eosinophilic Esophagitis (EoE), often described as the "asthma of the esophagus," is a chronic, immune-mediated Type 2 inflammatory disease characterized by dense eosinophilic infiltration of the esophageal mucosa, leading to progressive structural remodeling and functional impairment. The disease is driven by Th2-mediated immune pathways and is strongly associated with atopic conditions such as asthma, allergic rhinitis, eczema, and food allergies. Diagnosis is confirmed via endoscopic biopsy demonstrating ≥15 eosinophils per high-power field (eos/hpf), localized to the esophagus.

EoE presents with age-dependent clinical manifestations: Pediatric patients commonly experience vomiting, abdominal pain, regurgitation, and feeding difficulties, while adolescents and adults typically present with dysphagia, food impaction, and chest discomfort, often linked to fibrostenotic changes.

The disease follows a progressive course, transitioning from inflammatory to fibrostenotic phenotypes if not adequately managed.

Current treatment strategies include proton pump inhibitors (PPIs), topical corticosteroids (e.g., budesonide, fluticasone), dietary management, and biologics (e.g., dupilumab) in moderate-to-severe cases. For patients with refractory or severe disease, biologic therapies such as dupilumab (IL-4/IL-13 inhibitor) have significantly advanced treatment by targeting the underlying immunological pathways.

Despite therapeutic advancements, EoE remains a chronic, relapsing condition requiring long-term management, with no curative or disease-modifying therapies currently available.

Key Highlights

  • The incident EoE population in the United States is estimated at 27,008 cases in 2025, increasing to 28,897 by 2035, reflecting a steady rise driven by improved diagnosis and awareness.
  • The prevalent population is significantly larger, projected to grow from 53,671 in 2025 to 57,423 by 2035, highlighting the chronic nature of the disease and long patient duration.
  • The diagnosed population is estimated at 46,693 in 2025, increasing to 49,958 by 2035, indicating gradual improvement in diagnosis rates but still suggesting a gap between prevalence and diagnosis.
  • A male predominance is observed, with male cases vs female cases increasing by 2035 (2.2:1 ratio).
  • EoE affects a broad age range, with the highest burden observed in young and middle-aged adults (21-40 years), though pediatric cases remain clinically significant.
  • Disease severity is largely skewed toward moderate cases, followed by severe and mild segments.
  • Dysphagia is the most common symptom, affecting 29,948 patients in 2025, increasing to 32,042 by 2035, followed by abdominal pain/dyspepsia and esophageal structural complications.

Market Overview

  • The EoE treatment market in the US is projected to grow from $271 million in 2025 to $370 million by 2035, reflecting a CAGR of 3.2-3.5% over the forecast period.
  • Short-term growth (2025-2030) is relatively stronger, driven by increased adoption of biologics and improved diagnosis rates.
  • PPIs dominate the market (36-40% share), remaining first-line therapy due to cost-effectiveness and accessibility.
  • Topical corticosteroids (fluticasone, budesonide) account for 25-30% combined share.
  • Biologics (Dupixent/dupilumab) represent a high-growth segment, with share increasing steadily from 4% in 2025 to 4.6%+ by 2035.
  • Emerging therapies such as AK002 (lirentelimab), tezepelumab, and APT-1011 contribute incremental revenue, collectively reaching $70M+ by 2035
  • Pharmacological therapies dominate, while dietary and supportive therapies contribute smaller shares but remain clinically relevant.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

  • Sanofi
  • AstraZeneca
  • NexEos Diagnostics, Inc.
  • Celldex Therapeutics
  • Eupraxia Pharmaceuticals Inc.
  • Revolo Biotherapeutics
  • Celgene
  • Ellodi Pharmaceuticals, LP
  • Phathom Pharmaceuticals, Inc.
  • AQILION AB
  • Uniquity One (UNI)
  • Regeneron Pharmaceuticals

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies - profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
    • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)